home / stock / kmph / kmph news

KMPH News and Press, KemPharm Inc From 11/10/21

Stock Information
Company Name: KemPharm Inc
Stock Symbol: KMPH
Market: NASDAQ
Website: kempharm.com
Menu
KMPH KMPH Quote KMPH Short KMPH News KMPH Articles KMPH Message Board
Get KMPH Alerts

News, Short Squeeze, Breakout and More Instantly...
KMPH - KemPharm Reports Third Quarter 2021 Financial Results and Corporate Updates

Lead Independent Director Richard W. Pascoe Named Executive Chairman Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, November 10, 2021, 4:30 p.m. ET Corporate and Regulatory Highlights Appointment of Richard W. Pascoe as Execut...
KMPH - Notable earnings after Wednesday's close

OTCQX:ACRGF, ADMA, AEVA, DADAAMPE, AMWL, APP, APPH, ASND, ATO, OTCPK:ATUSF, AZUL, BANX, BARK, BIOL, BKEP, BMBL, BOXL, BRFS, BRKS, BROS, BSQR, BW, BYND, BZH, CBAY, CCCS, CCMP, CGRN, CLSD, CLVR, CRCT, CYCC, DARE, DGII, DIS, EDRY, EGLX, ELMS, ENS, EVOK, FICO, FIGS, FOSL, FSM, GAU, GDRX, GEVO, OT...

KMPH - KemPharm Announces AZSTARYS® Clinical Data to be Featured in Poster Presentation at the 2021 Virtual International Conference on ADHD

Data demonstrate efficacy of AZSTARYS in children, including 30-minute onset of action and 13-hour duration of effect Corium Continues Commercialization Effort in U.S. CELEBRATION, Fla., Nov. 05, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmac...

KMPH - KemPharm to Report Third Quarter 2021 Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesday, November 10, 2021, 4:30 p.m. ET CELEBRATION, Fla., Nov. 03, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development o...
KMPH - AZSTARYS®, An Innovative ADHD Treatment Developed by KemPharm, to be Featured in a Poster Presentation at the 2021 Psych Congress

Pharmacokinetic data from two clinical studies of AZSTARYS demonstrated its rapid onset of action and long duration of effect CELEBRATION, Fla., Oct. 27, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and devel...

KMPH - KemPharm Announces Research Involving AZSTARYS® and Serdexmethylphenidate to be Featured in Poster Presentations at Multiple Medical Conferences during ADHD Awareness Month (October)

CELEBRATION, Fla., Oct. 20, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that research involving AZSTARYS ® and serdexmethylphenidate (SDX), the ...

KMPH - KemPharm, Inc. Announces Uplisting to The Nasdaq Global Select Market

Trading to commence effective with the open of business on October 19, 2021 CELEBRATION, Fla., Oct. 19, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced&...
KMPH - KemPharm (KMPH) Investor Presentation - Slideshow

The following slide deck was published by KemPharm, Inc. in conjunction with this event. For further details see: KemPharm (KMPH) Investor Presentation - Slideshow

KMPH - KemPharm to Present at the Benzinga Healthcare Small Cap Conference

CELEBRATION, Fla., Sept. 27, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and Chief Executive Officer of KemPharm...

KMPH - KemPharm to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

CELEBRATION, Fla., Sept. 23, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and Chief Executive Officer of KemPharm...
Previous 10 Next 10